Descriptive summary: use of a compound with the formula (I) ##STR1##
where
R1 is a hydrogen atom, a C1-2 alkyl group, a C1-2 fluoroalkyl group or a C1-2 perfluoroalkyl group and R2, R3 and R4, which may be the same or different, all represent a hydrogen atom, a straight- or branched-chain C1-4 alkyl group or a C3-4 cycloalkyl group, and
R5 is a hydrogen atom, a halogen such as fluorine or chlorine, a C1-4 alkyl group or a straight- or branched-chain C1-4 alkoxy group to manufacture a medicinal agent which can be used to treat ejaculation problems such as retrograde ejaculation or aspermia.
|
1. A method to contract the smooth muscles of the fornix which comprises administering to a patient in need of such treatment an effective amount of a compound with the formula (I) ##STR4##
where R1 is a hydrogen atom, a C1-2 alkyl group, a C1-2 fluoroalkyl group or a C1-2 perfluoroalkyl group and R2, R3 and R4, which may be the same or different, all represent a hydrogen atom, a straight- or branched-chain C1-4 alkyl group or a C3-4 cycloalkyl group, and R5 is a hydrogen atom, a halogen, a C1-4 alkyl group or a straight- or branched-chain C1-4 alkoxy group in the form of an enantiomer, diastereoisomer or a mixture of these forms, including a racemic mixture, as well as the addition salts with pharmaceutically acceptable acids. 2. A method according to
3. A method according to
4. A method according to
5. A method according to
6. A method according to
7. A method according to
8. A method according to
10. A method according to
11. A method according to
16. A method according to
|
|||||||||||||||||
This application is a 371 of PCT/FR98/01928 Sep. 10, 1998.
The object of the present invention is the use of sulfonanilide derivatives to produce a medicinal product intended for the treatment of retrograde ejaculation or aspermia.
The compounds have the following general formula (I) ##STR2##
where
R1 is a hydrogen atom, a C1-2 alkyl group, a C1-2 fluoroalkyl group or a C1-2 perfluoroalkyl group, and R2, R3 and R4, which may be the same or different, all represent a hydrogen atom, a straight- or branched-chain C1-4 alkyl group or a C3-4 cycloalkyl group, preferably a hydrogen or a methyl and
R5 is a hydrogen atom, a halogen such as fluorine or chlorine, a C1-4 alkyl group or a straight- or branched-chain C1-4 alkoxy group, preferably a methoxy or a halogen and more particularly a fluorine.
The compounds with the general formula (I) may include one or several asymmetric carbons. They can therefore exist in the form of enantiomers or diastereoisomers. These enantiomers, diastereoisomers and mixtures of them, including racemic mixtures, form part of the invention.
The compounds with the general formula (I) may take the form of the free base or addition salts with pharmaceutically acceptable acids, which are also part of the invention.
The compounds with the general formula (I) can be prepared according to the procedures described in European Patent EP 538469 or analog procedures known to specialists.
The table which follows illustrates, by way of example, the structure of some compounds which can be used according to the invention, without however limiting the invention to these compounds.
| TABLE |
| (I) |
| ##STR3## |
| Number R1 R2 R3 R4 R5 base/salt |
| MPt(° C) |
| 1(-) H H H CH3 F HCl 185 |
| 2(+) H H H CH3 F HCl 203-220 |
| 3 H H H CH3 OCH3 CH3 SO3 H 180-182 |
| (-) indicates an 1-enantiomer and (+) indicates a d-enantiomer |
The compounds of the invention have been submitted to biological tests intended to demonstrate their contractile activity on the smooth muscles of the fornix and the arteries.
The in-vitro activity of the compounds of the invention has been investigated on the smooth muscles of the fornix and the arteries. These tests were carried out on New-Zealand rabbits weighing between 3 and 3.5 kg. The animals were killed by cervical dislocation and then rings were prepared from the tissue of the mesenteric arteries and strips from the fornix. The rings or strips of tissue were immersed in modified Krebs' solution which was oxygenated with a mixture containing 95% O2 and 5% CO2. Each tissue sample was subjected to a tension of 1 g and then cumulative doses of phenylephrine were added and the concentration/response curve plotted. After rinsing the tissue, the test compound was added at cumulative doses and the concentration/response curve plotted. The contractile effect of each compound was assessed by calculating the value of pD2 (the negative logarithm of the concentration of the agonist which induces 50% of the maximum contraction) and the maximum effect, expressed as a percentage of the contraction obtained with phenylephrine (% Emax).
The results obtained show that the compounds corresponding to the invention, display:
a pD2 of the fornix, which is usually between 4 and 6
a pD2 of the artery which is usually less than 5
a % Emax phenylephrine for the fornix which is greater than 30% and usually between 40 and 90%
a % Emax for the artery which is usually greater than 30%
All the above data show that the compounds according to the invention have a strong contractile effect on the smooth muscles of the fornix and a weak contractile effect on the artery.
They can be used for medicinal purposes, particularly as an agent to contract the smooth muscles of the fornix, and more particularly still, to treat ejaculation problems such as retrograde ejaculation or aspermia. In this indication, the compounds according to the invention demonstrate good efficacy and usually, less side effects than the drugs conventionally used for such treatment, notably with regard to side effects involving the cardiovascular system.
The compounds according to the invention can be formulated in various appropriate pharmaceutical forms for administration by the digestive or parenteral routes as required and combined with at least one pharmaceutical excipient. The appropriate pharmaceutical forms consist, for example, of tablets, capsules, sugar-coated tablets, solutions for oral use or for injection, syrups and suppositories.
These pharmaceutical forms can contain sufficient quantities to permit a daily dose of 1 μg/kg to 30 mg/kg.
Martin, Denis, Angel, Itzchak, Arbilla, Sonia
| Patent | Priority | Assignee | Title |
| Patent | Priority | Assignee | Title |
| 5610174, | Jun 02 1995 | H LUNDBECK A S | Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence |
| 5922341, | Oct 28 1997 | VIVUS, INC | Local administration of pharmacologically active agents to treat premature ejaculation |
| 5958884, | Apr 11 1997 | The Brigham and Women's Hospital, Inc. | Compositions and methods for treating erectile dysfunction |
| 6037346, | Oct 28 1997 | VIVUS, INC | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| 6071882, | Sep 12 1996 | Zentaris GmbH | Means for treating prostate hypertrophy and prostate cancer |
| 6071915, | May 12 1997 | ORCHO-MCNEIL PHARMACEUTICAL, INC | Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia |
| EP538469, | |||
| WO9706136, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Mar 22 2000 | Sanofi-Synthelabo | (assignment on the face of the patent) | / | |||
| Apr 25 2000 | ANGEL, ITZCHAK | Sanofi-Synthelabo | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 010845 | /0180 | |
| May 12 2000 | MARTIN, DENIS | Sanofi-Synthelabo | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 010845 | /0180 | |
| May 15 2000 | ARBILLA, SONIA | Sanofi-Synthelabo | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 010845 | /0180 |
| Date | Maintenance Fee Events |
| Jan 05 2005 | REM: Maintenance Fee Reminder Mailed. |
| Jun 20 2005 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| Date | Maintenance Schedule |
| Jun 19 2004 | 4 years fee payment window open |
| Dec 19 2004 | 6 months grace period start (w surcharge) |
| Jun 19 2005 | patent expiry (for year 4) |
| Jun 19 2007 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Jun 19 2008 | 8 years fee payment window open |
| Dec 19 2008 | 6 months grace period start (w surcharge) |
| Jun 19 2009 | patent expiry (for year 8) |
| Jun 19 2011 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Jun 19 2012 | 12 years fee payment window open |
| Dec 19 2012 | 6 months grace period start (w surcharge) |
| Jun 19 2013 | patent expiry (for year 12) |
| Jun 19 2015 | 2 years to revive unintentionally abandoned end. (for year 12) |